These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38924597)

  • 21. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.
    Dumon JC; Magritte A; Body JJ
    Bone Miner; 1991 Dec; 15(3):257-66. PubMed ID: 1773138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β.
    Duesterdieck-Zellmer KF; Driscoll N; Ott JF
    Am J Vet Res; 2012 Oct; 73(10):1530-9. PubMed ID: 23013178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective evaluation of acute kidney injury in horses treated with nonnitrogenous bisphosphonates (2013-2020): 8 cases.
    Edwards L; Magdesian KG
    J Vet Emerg Crit Care (San Antonio); 2023; 33(6):685-695. PubMed ID: 37695208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
    Morales-Piga A
    Expert Opin Pharmacother; 1999 Nov; 1(1):157-70. PubMed ID: 11249559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractures of the tuber coxa of the ilium in horses: 29 cases (1996-2007).
    Dabareiner RM; Cole RC
    J Am Vet Med Assoc; 2009 May; 234(10):1303-7. PubMed ID: 19442027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human pharmacokinetics of tiludronate.
    Sansom LN; Necciari J; Thiercelin JF
    Bone; 1995 Nov; 17(5 Suppl):479S-483S. PubMed ID: 8573422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
    Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
    J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat.
    Rohanizadeh R; LeGeros RZ; Bohic S; Pilet P; Barbier A; Daculsi G
    Calcif Tissue Int; 2000 Oct; 67(4):330-6. PubMed ID: 11000348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses.
    Hunter BG; Duesterdieck-Zellmer KF; Larson MK
    PeerJ; 2015; 3():e889. PubMed ID: 25945303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone.
    Morales-Piga A; Del Pino J; Rapado A; Diaz-Curiel M; Pallares M; Gonzalez-Macias J
    Clin Ther; 1997; 19(5):963-74. PubMed ID: 9385484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiludronate: bone pharmacology and safety.
    Bonjour JP; Ammann P; Barbier A; Caverzasio J; Rizzoli R
    Bone; 1995 Nov; 17(5 Suppl):473S-477S. PubMed ID: 8573421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scintigraphic abnormalities of the pelvic region in horses examined because of lameness or poor performance: 128 cases (1993-2000).
    Davenport-Goodall CL; Ross MW
    J Am Vet Med Assoc; 2004 Jan; 224(1):88-95. PubMed ID: 14710883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
    Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
    Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of mild hindlimb lameness during over ground locomotion using linear discriminant analysis of inertial sensor data.
    Pfau T; Robilliard JJ; Weller R; Jespers K; Eliashar E; Wilson AM
    Equine Vet J; 2007 Sep; 39(5):407-13. PubMed ID: 17910264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tiludronate on bone loss in paraplegic patients.
    Chappard D; Minaire P; Privat C; Berard E; Mendoza-Sarmiento J; Tournebise H; Basle MF; Audran M; Rebel A; Picot C
    J Bone Miner Res; 1995 Jan; 10(1):112-8. PubMed ID: 7747617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in gait parameters used for objective lameness assessment in sound horses at the trot on the straight line and the lunge.
    Hardeman AM; Serra Bragança FM; Swagemakers JH; van Weeren PR; Roepstorff L
    Equine Vet J; 2019 Nov; 51(6):831-839. PubMed ID: 30648286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
    Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M
    Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.